Proactive Investors - Run By Investors For Investors

Namaste rejects dried cannabis supply from Bonify

Namaste's subsidiary CannMart rejected dried cannabis from the cannabis producer Bonify, which was the subject of a recall by Health Canada on December 7
cannabis plant
Namaste sells medical cannabis in Canada via CannMart.com

Namaste Technologies Inc (CVE:N) (OTCMKTS:NXTTF) said Friday that its subsidiary CannMart rejected dried cannabis from the cannabis producer Bonify, which was the subject of a recall by Health Canada on December 7.

The relevant product was immediately returned to Bonify. CannMart has also suspended further purchases and products it previously purchased from Bonify until Health Canada delivers instructions and adequate independent testing is performed.

Namaste operates a global cannabis e-commerce platform with over 30 web sites in 20 countries under various brands. Through its subsidiaries, Namaste’s product offerings include vaporizers, glassware, accessories and CBD products. It also sells medical cannabis in Canada through its licensed subsidiary CannMart.com

Shares of Namaste dropped C$0.03 to C$0.78 in Friday’s Canadian trading. They were down US$0.05 to US$0.56 on the OTC Markets.

Contact Ellen Kelleher at [email protected]

View full N profile View Profile

Namaste Technologies Inc Timeline

Related Articles

scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
A stomach adenocarcinoma
February 12 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use